Cancer & Metabolism

Cancer & Metabolism accepted for inclusion in SCIE

We are delighted to announce that Cancer & Metabolism has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Cancer & Metabolism will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.

We would like to thank everyone for supporting Cancer & Metabolism and contributing to this success.

New Reviewer Recruitment

Cancer & Metabolism invites you to join our team of reviewers. For consideration, please send your CV with keywords and expertise to rosie.daniel@springer.com.

2019 Article Collection: Breast Cancer and Metabolism

The biology of tumor cells in breast cancer is complex and relatively unexplored. Cancer & Metabolism is excited to present the following article highlights that identify novel biomarkers and metabolic profiles of different breast cancer subtypes.

- Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities

- Metabolomics of oncogene-specific metabolic reprogramming during breast cancer

- Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation

- Activation of pro-survival metabolic networks by 1,25(OH)2D3 does not hamper the sensitivity of breast cancer cells to chemotherapeutics

- The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer

Featured article: Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Tronstad et al. investigated the role the role of succinate dehydrogenase in relation to Epithelial to mesenchymal transition (EMT) in breast cancer progression and therapy.

Editorial Board

Dr. Michael Pollak, co-Editor-in-Chief

Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.

"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."

Dr. Matthew G. Vander Heiden, co-Editor-in-Chief

Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).

Editorial Board Members

Abass Alavi, University of Pennsylvania School of Medicine, USA
Lewis Cantley, Weill Cornell Medical College, USA
Peter Carmeliet, Vesalius Research Center, Belgium
Ralph DeBerardinis, University of Texas Southwestern Medical Center, USA
Teresa Fan, Markey Cancer Center, USA
Robert Gatenby, H. Lee Moffitt Cancer Center and Research Institute, USA
Kun-Liang Guan, University of California, San Diego,
Rudolf Kaaks, German Cancer Research Center, Germany
Andrew Lane, Markey Cancer Center, USA
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA
Lorenz Poellinger, Karolinska Institute, Sweden
Jacques Pouyssegur, Institute of Research on Cancer and Aging, France
Joshua Rabinowitz, Princeton University, USA
Peter Ratcliffe, Nuffield Department of Clinical Medicine, UK

Jeffrey Rathmell, Duke University, USA
Jared Rutter, University of Utah School of Medicine, USA
David Sabatini, Whitehead Institute for Biomedical Research, USA
Paolo Sassone-Corsi, University of California, Irvine, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA
Celeste Simon, University of Pennsylvania School of Medicine, USA
Alexei Vazquez, The Cancer Institute of New Jersey, USA
Bert Vogelstein, Johns Hopkins University School of Medicine, USA
Karen Vousden, Beatson Institute for Cancer Research, UK
Kathryn Wellen, University of Pennsylvania, USA
Eileen White, The Cancer Institute of New Jersey, USA
Yue Xiong, University of North Carolina, Chapel Hill, USA

Chi Van Dang, Editor Emeritus

Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.

"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."

Metabolic models predict bacterial passengers in colorectal cancer

Authors: Daniel R. Garza, Rahwa Taddese, Jakob Wirbel, Georg Zeller, Annemarie Boleij, Martijn A. Huynen and Bas E. Dutilh

Content type: Research

10 February 2020
Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy

Authors: Barbara S. Nelson, Lin Lin, Daniel M. Kremer, Cristovão M. Sousa, Cecilia Cotta-Ramusino, Amy Myers, Johanna Ramos, Tina Gao, Ilya Kovalenko, Kari Wilder-Romans, Joseph Dresser, Mary Davis, Ho-Joon Lee, Zeribe C. Nwosu, Scott Campit, Oksana Mashadova…

Content type: Research

2 January 2020
Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells

Authors: Lei Yu, Shao Thing Teoh, Elliot Ensink, Martin P. Ogrodzinski, Che Yang, Ana I. Vazquez and Sophia Y. Lunt

Content type: Research

30 December 2019
A systematic flux analysis approach to identify metabolic vulnerabilities in human breast cancer cell lines

Authors: Sheree D. Martin and Sean L. McGee

Content type: Research

27 December 2019
HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells

Authors: Albertus T. J. Wierenga, Alan Cunningham, Ayşegül Erdem, Nuria Vilaplana Lopera, Annet Z. Brouwers-Vos, Maurien Pruis, André B. Mulder, Ulrich L. Günther, Joost H. A. Martens, Edo Vellenga and Jan Jacob Schuringa

Content type: Research

27 December 2019

Most recent articles RSS

View all articles

Linking vitamin B1 with cancer cell metabolism

Authors: Jason A Zastre, Rebecca L Sweet, Bradley S Hanberry and Star Ye

Content type: Review

24 July 2013
Calorie restriction and cancer prevention: a mechanistic perspective

Authors: Stephen D Hursting, Sarah M Dunlap, Nikki A Ford, Marcie J Hursting and Laura M Lashinger

Content type: Review

7 March 2013
Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways

Authors: Norma Masson and Peter J Ratcliffe

Content type: Review

4 February 2014
Metformin directly acts on mitochondria to alter cellular bioenergetics

Authors: Sylvia Andrzejewski, Simon-Pierre Gravel, Michael Pollak and Julie St-Pierre

Content type: Research

28 August 2014
Mitochondria as biosynthetic factories for cancer proliferation

Authors: Christopher S Ahn and Christian M Metallo

Content type: Review

25 January 2015

Most accessed articles RSS

View all articles

Efficient peer review

We recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. As a niche journal, Cancer & Metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal.

Cancer & Metabolism